This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
4i77
From Proteopedia
| Line 1: | Line 1: | ||
| - | [[Image:4i77.jpg|left|200px]] | ||
| - | |||
{{STRUCTURE_4i77| PDB=4i77 | SCENE= }} | {{STRUCTURE_4i77| PDB=4i77 | SCENE= }} | ||
| - | |||
===Lebrikizumab Fab bound to IL-13=== | ===Lebrikizumab Fab bound to IL-13=== | ||
| + | {{ABSTRACT_PUBMED_23357170}} | ||
| - | + | ==Disease== | |
| + | [[http://www.uniprot.org/uniprot/IL13_HUMAN IL13_HUMAN]] Defects in IL13 may be a cause of susceptibility to allergic rhinitis (ALRH) [MIM:[http://omim.org/entry/607154 607154]]. Allergic rhinitis is a common disease of complex inheritance and is characterized by mucosal inflammation caused by allergen exposure. | ||
| + | |||
| + | ==Function== | ||
| + | [[http://www.uniprot.org/uniprot/IL13_HUMAN IL13_HUMAN]] Cytokine. Inhibits inflammatory cytokine production. Synergizes with IL2 in regulating interferon-gamma synthesis. May be critical in regulating inflammatory and immune responses. | ||
==About this Structure== | ==About this Structure== | ||
Revision as of 19:16, 17 April 2013
Contents |
Lebrikizumab Fab bound to IL-13
Template:ABSTRACT PUBMED 23357170
Disease
[IL13_HUMAN] Defects in IL13 may be a cause of susceptibility to allergic rhinitis (ALRH) [MIM:607154]. Allergic rhinitis is a common disease of complex inheritance and is characterized by mucosal inflammation caused by allergen exposure.
Function
[IL13_HUMAN] Cytokine. Inhibits inflammatory cytokine production. Synergizes with IL2 in regulating interferon-gamma synthesis. May be critical in regulating inflammatory and immune responses.
About this Structure
4i77 is a 3 chain structure with sequence from Homo sapiens. Full crystallographic information is available from OCA.
